🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

24 recruiting trials

for Lymphohistiocytosis

Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis NCT07488728NA1 site📍 Beijing Beijing Children's Hospital · Tests: Letermovir Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC NCT04528355n/a1 site📍 Pittsburgh Paul Szabolcs · Tests: data collection Golidocitinib Combined With Selinexor for CAEBVD NCT07369739Phase 2, Phase 31 site📍 Beijing Beijing Friendship Hospital · Tests: golidocitinib, Selinexor (combination therapy) A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS]) NCT07208058Phase 318 sites📍 Beijing📍 Beijing📍 Beijing TJ Biopharma Co., Ltd. · Tests: Plonmarlimab Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a2 sites📍 Sioux Falls📍 Sydney Sanford Health Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) NCT07424222Phase 11 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: Ruxolitinib CytOSorb TreatMent Of Critically Ill PatientS Registry NCT05146336n/a28 sites📍 Klagenfurt📍 Vienna📍 Aachen CytoSorbents, Inc · Tests: CytoSorb Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) NCT06160791Phase 24 sites📍 Irvine📍 Sacramento📍 San Diego Jerry Lee, MD, MSc, MPhil · Tests: Ruxolitinib, Etoposide, Dexamethasone, Non-interventional Imaging, Research Biopsy Assessing the Presence of CT-DNA in Lymphoma Associated HLH NCT05702502n/a1 site📍 Nottingham Nottingham University Hospitals NHS Trust INTO-HLH: A Disease Registry for Patients With Hemophagocytic Lymphohistiocytosis (HLH) NCT05277272n/a1 site📍 Cincinnati Children's Hospital Medical Center, Cincinnati Prospective Cohort for Adult Hemophagocytosis NCT03117010n/a1 site📍 Seoul Samsung Medical Center · Tests: Steroids, Etoposide A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH NCT05936086NA1 site📍 Chongqing shifeng Lou · Tests: Cytoxan, Etoposide, Dexamethasone, Cyclosporine (CSA) Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH) NCT05762640Phase 21 site📍 Paris Assistance Publique - Hôpitaux de Paris · Tests: Ruxolitinib Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study NCT06339177n/a2 sites📍 Bethesda📍 Pittsburgh National Institute of Allergy and Infectious Diseases (NIAI… Establishing a National Egyptian HLH Registry (NEHR) NCT07800234n/a2 sites📍 Cairo📍 Cairo Ain Shams University Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis NCT05898477n/a1 site📍 Birmingham University of Alabama at Birmingham Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma NCT07270835Phase 41 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: Rituximab, Zanubrutinib Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH) NCT05416307Phase 2, Phase 342 sites📍 Birmingham📍 Phoenix📍 Los Angeles Electra Therapeutics Inc. · Tests: ELA026 Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection NCT03491605n/a1 site📍 Wuhan Huazhong University of Science and Technology · Tests: peripheral EBV-DNA load Prospective Validation of the OHI Index NCT05882175n/a2 sites📍 Kfar Saba📍 Petah Tikva Meir Medical Center Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection NCT06135922Phase 11 site📍 Beijing Chinese PLA General Hospital · Tests: EBV-TCR-T cells Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT NCT01962415Phase 21 site📍 Pittsburgh Paul Szabolcs · Tests: Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa Prospective Single-Arm Clinical Trial of GO Regimen for HLH. NCT07339345Phase 2, Phase 31 site📍 Beijing Beijing Friendship Hospital · Tests: Golidocitinib Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) NCT07525466Phase 1, Phase 21 site📍 Beijing Beijing Tongren Hospital · Tests: Mitoxantrone liposome, Etoposide, Pegaspargase (PEG) Asparaginase, methylprednisolone, golidocitinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy